Brittany Barreto founded the first nationwide DNA-based dating app, and she shares her story of its unexpected, and unavoidable, downfall. Photo courtesy of Pheramor

When Brittany Baretto was 18 years old and sitting in an undergraduate genetics seminar, she raised her hand. She asked, to her professor's point, if particular DNA trait differences between two people can result in attraction, could she, based on that logic, make a DNA-based dating tool. With that question, she set in motion a series of events.

These events included teaming up with Bin Huang to start a dating app, called Pheramor, that factored in user DNA; raising millions for the company; hiring a team from across the country; and signing up users in all 50 states. Though, Pheramor's hockey stick growth came to a sudden stop this year when Apple pulled the app from its store, and there was nothing the founders or their investors could do about it.

"They are gatekeepers in innovation," Barreto learned the hard way.

InnovationMap recently spoke with Barreto to discuss the rise and fall of Pheramor and lessons learned.

Launching the first nationwide DNA-based dating app

Barreto mulled over the idea for the company through college and through her genetics PhD program before starting the company in 2017.

"I actually formed the C-Corp the same month that Accenture put out its report on Houston needing more attention on its startups and innovation," she says. "I didn't know about that report. I was really lucky with Pheramor to ride the wave of Houston growing its startup community."

She went on to fundraise $1.3 million, and, at its height, Pheramor had 10 employees working out of WeWork in the Galleria. Pheramor was the first nationwide DNA-based dating app, and for that she will always be proud, Barreto says.

"We were growing something not necessarily unicorn status growth, but we were doing something really different," she says. "And we knew we were growing something valuable. At our peak, we had 250 downloads a day."

Venture capitalists were taking note, Barreto says, and she was on her way to closing another round — this time for $2.2 million.

Getting the call

In March, Barreto and Huang attended Enventure's bioventure pitch event, where, just three years prior, the duo had pitched and won thousands of dollars. It was a real turning point, Barreto remembers.

Earlier that day, they had seen some issues with Apple's app store and filed a service request. As she left the event, Barreto's phone rang, and it was an Apple representative explaining that the Pheramor app had been pulled from the store. New rules for the App Store had been set in place — rules that forbid dating apps from procuring DNA samples from users.

Once the DNA element was removed from the app, Pheramor would be allowed back on, Barreto was told.

"That was our differentiator," she says. "That was the thing that made us Pheramor."

For the next three weeks, Barreto called every app reviewer at Apple and challenged each "no" she got.

"I had that internal founder drive. I was like, 'No, I just need to talk to someone. I'm going to hustle around this.'"

Her request went to the very top, before receiving one final, inarguable "No."

Barreto knows why Apple instituted the new policy — biohackers are the newest cyber threat in the world. But she was being dragged through the ringer while watching her startup slowly slip away, and the anonymous Apple employees on the other end of the phone had no sympathy for her inner turmoil.

"It felt like they just kept reading a script," she says, adding that it was the most painful experience for her. "The insensitivity of the app review people was salt in the wound."

Throwing a Hail Mary

The Pheramor app was still live on Google, Barreto says, but with only 10 percent of the market, and data showing that Android users are historically non-buyers, she knew she had to pivot.

Huang and his team turned around an idea for a couples' compatibility test based on DNA, and WeHaveChemistry.com was born. Barreto tapped an acclaimed relationship expert, Laura Berman, as a strategic adviser. She made a deal with her board — if they could sell 100 of these kits in 60 days, they'll make new goals and keep the testing live.

Barreto says they sold some, but ultimately in June, after not meeting that goal, she suggested to the board the company should sell its assets, if possible, to help pay back her investors.

While the investors of Pheramor's $2.2 million round had pulled out at this point, Pheramor still had $100,000 in the bank. Barreto says she budgeted about $30,000 to legally close the company. At this point, she had laid off her staff, and it was down to the co-founders. Both got new jobs — Huang is now the head data scientist at Houston-based BrainCheck, and Barreto joined Capital Factory as its Houston-based venture associate.

Since Barreto was actively trying to sell the assets, she kept quiet about Pheramor's downfall. While she had some interest, ultimately, people told her the technology was too complicated or that they wouldn't buy unless Barreto came with the company.

"I realized that over the past two years, I had already been ad hoc coaching and mentoring founders and loving it," Barreto says. "Now, I was doing it and getting paid for it, on a bigger scale, and with more resources. I knew it was the journey I wanted to continue down."

Lessons thoroughly learned

Barreto's past six months have been a rollercoaster, to say the least. Losing Pheramor felt like an identity crisis for her.

"I was very personally involved with the brand," she says. "So when Pheramor was gone, it was like, 'Who am I?'"

She had to keep most of her inner turmoil hidden from the startup community, especially since she was trying to sell Pheramor's assets. She battled an eating disorder and lost chunks of her hair, all the while she felt like she had to keep a smile on her face.

"As a female founder, I felt so much pressure to win. It felt like stakes were higher for me," Barreto says. "I felt really nervous to let my insides show."

She did find a few entrepreneurs that helped to guide her with their own perspective and careers, and Barreto says she leaned on her lawyer, Nicole Moss, a Houston-area startup lawyer, to help talk her through things. One surprising confidant was one of her investors, Jack Gill.

Barreto remembers meeting with Gill and thinking she was about to have to apologize for losing a ton of his money, but instead, he hugged her and congratulated on her first failure — that Pheramor's demise made her a real entrepreneur.

"His pride was a big turning point for me. I realized, 'Wow, this is really a jumping off point,'" she says.

This, of course, was directly contrasted by other investor's extreme disappointment. In the end, Barreto paid back investors by about 5 percent. She also realized the difference of working with investors who are new to the process.

"I learned a lesson of taking money from people who are not experienced investors will cause you headaches along the way," she says.

What's next? Funding femtech.

These investor lessons learned are especially important to Barreto, who wants her next startup to be a venture fund focused on empowering the marginalized entrepreneurs — female founders, the LGBT community, minorities, etc.

"I want to be someone of influence for social good," she says. "This crazy idea I had for a dating app was just a way to propel me to becoming that person. I felt like it did that."

Flipping to the other side of the investor table is appealing to Barreto, because she feels like she's able to make more of an impact.

"What I learned from Pheramor is I put all my eggs in one basket, and something happened and all my eggs broke," she says. "As a VC, you put your eggs in lots of baskets. If I want to make big change, I can probably do that more effectively if I'm empowering 20 different companies instead of doing only one thing."

Her idea is to raise a femtech fund that invests in startups and entrepreneurs with products or services within women's health.

"For me, as long as you're working on a technology that improves women's health and wellness, I want to invest in you," she says.

It's taken her a long time to get to this point, but ultimately, Barreto has realized that she did everything she could do, and she's better for this journey — no matter how rough it is. More importantly to Barreto, she sees this as an opportunity to share her story of failure — though, she wishes there were a better word for it — so that other entrepreneurs don't feel so alone in the process. She hopes that Pheramor's legacy can fill that need.

"We need to get comfortable with failure and support each other in the journey," she says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Baylor College of Medicine launches VC fund to invest in biotech startups

fresh funding

Houston’s Baylor College of Medicine just unveiled a new venture capital fund that backs early-stage biotech startups—and it’s already made its first investment.

BCM Legacy Fund I, funded by philanthropies, invested an undisclosed amount in Houston biotech startup Nemea Therapeutics. Nemea, a spinout of the Baylor College of Medicine and Germany’s Lead Discovery Center, is developing an oral drug to treat metastatic triple-negative breast cancer that no longer responds to currently available therapies.

This type of aggressive cancer spreads from the breast to other areas of the body, such as the bones, liver, lungs or brain. Roughly 38,000 to 57,000 Americans are diagnosed each year with metastatic triple-negative breast cancer. One study showed about half of patients survive past the one-year mark following diagnosis and about one-third survive two years.

“Baylor College of Medicine’s laboratories produce discoveries with the potential to change patients’ lives, and too many of them stall where academic funding ends and private investment has not yet begun,” Dr. Jakub Tolar, president, CEO and executive dean of the Baylor College of Medicine, said in a press release. “The BCM Legacy Fund fills that gap, giving our scientists a path to advance their discoveries to patients.”

The National Institutes of Health awards more than $36 billion per year for biomedical research in the U.S., Baylor said. But some biomedical discoveries “never leave the starting line because they don’t yet fit the economics of venture capital,” the college said.

“The forefront of a new model”

The BCM Legacy Fund aggregates philanthropic capital from private foundations and donor-advised funds. It then invests in startups so they can move beyond that starting line and into later-stage investment rounds. The Greater Houston Community Foundation is the fund’s philanthropic partner.

“It’s exciting to be on the forefront of a new model for philanthropic capital,” said Houston entrepreneur and investor Burton Hanson, managing partner of the fund.

“Not only do we hope to solve a real problem by advancing these therapies to the patients who need them most, but we also hope this model will inspire others in the city and beyond toward philanthropic creativity and a posture of ‘I sacrifice; we win.’”

The fund expects to invest in about 15 early-stage startups over a five-year span. Baylor declined to divulge the amount of money in the fund and the size of the investment in Nemea.

Nemea’s “world-class chemistry”

Hanson oversees the Baylor fund alongside Chicago investor Steve Lehmann, who led the University of Chicago’s Innovation Fund.

Lehmann said Nemea, the fund’s first portfolio company, “has world-class chemistry, Baylor biology, and patients with no good options. Our job is to fund the experiments that carry it to the next handoff, so that industry and later-stage investors can take it from there.”

Based at Houston’s massive Texas Medical Center, Nemea plans to start clinical trials next year in collaboration with Baylor’s Lester and Sue Smith Breast Center.

Nemea previously received $9 million from the Lead Discovery Center and a $1.6 million grant from Baylor. Last year, the startup said it was seeking $25 million to $30 million in seed and Series A funding.

Debra McCoy of Houston, a former managing director at BlackRock and former partner at Bain & Co., and Paul Thomas, co-founder and CEO of Spring-based benefits manager Luscinia Health, sit on the Baylor fund’s governing board. Dr. Paul Klotman, former president, CEO and executive dean of Baylor, is a senior strategic adviser.

How does the fund find investment targets?

The Baylor Legacy Fund relies on two tools to help unearth early-stage biotech startups:

  • High-resolution “innovation maps” of research institutions. These maps surface hidden clusters of innovation, identify rising-star researchers and tie pockets of “innovation supply” at Baylor to areas of “innovation demand” in biotech.
  • AI-enhanced due diligence. AI agents assist with due diligence of early-stage biotech startups. The fund says the platform “distills the frameworks we’ve developed over a decade of teaching and investing into a flexible … diligence environment.”

MD Anderson unveils $3.4B expansion with two new Houston cancer care facilities

major expansion

The cutting edge of cancer-fighting technology and science is getting even sharper after MD Anderson announced last week that it will open two new facilities in the Texas Medical Center within the next five years. Inspiration Tower and Prism will expand MD Anderson’s annual patient load in the TMC to 250,000 annually and will incorporate a variety of new techniques.

The $3.4 billion project will add 2 million square feet to MD Anderson's TMC footprint, bringing its total campus size to 22 million square feet by 2032. Located at the corner of Fannin Street and Holcombe Boulevard, the cancer center says the two new facilities will serve as its new "front door" to the TMC.

“Every detail of these buildings, from the technology to the treatment rooms, was designed around our patients who will receive their care in them and our employees who will work in them. The facilities will serve as a physical representation of hope for the patients and their families who will walk through the doors,” Dr. Jeffrey E. Lee, president ad interim of UT MD Anderson, said in a news release. “Inspiration Tower and Prism are the future of cancer care, and we are grateful for the longstanding support and guidance we’ve received from the UT System Board of Regents to bring these projects to life. These facilities are part of the most impactful capital expansion in UT MD Anderson’s history.”

Prism is especially exciting as it will represent fully half of the linear accelerator treatment in the TMC. Linear accelerator is a radiation treatment that uses magnetically charged fields to deliver targeted external radiation therapy, like shooting cancer with a rail gun. The treatment is safer and has fewer side effects than older radiation treatments.

In addition, Prism will contain 12 MRI machines, four CT scanners, two PET-CT units, 18 radiation vaults and seven radiation simulators. Patient comfort has also been put at a premium with multiple gardens and roof overlooks.

“Every patient we treat deserves an environment that reflects the excellence of the care they receive at UT MD Anderson,” Chris McKee, executive vice president and chief strategy officer at UT MD Anderson, added in the release. “Our new facilities will be innovative, agile, adaptable and beautiful, and they will allow us to care for more patients, more effectively – in an environment that enhances healing and well-being. We are building for our future and for every patient who will be counting on us.”

Prism is slated to open in 2030.

Inspiration Tower will have 25 floors of surgical, diagnostic, and treatment services. At 1.4 million square feet, it’s currently expected to be the largest cancer-specific treatment facility in the United States. The tower will be divided into units for specific types of cancer, making it easy to integrate the advancing research being done all over Houston.

Like Prism, Inspiration Tower is specifically designed to offer comfort and reassurance, with more garden space, terraces, and beautiful scenery to ease patient distress. It is expected to open in 2032.

Tesla will pull the plug on Cybertruck production at Texas factory in 2027

Tesla Talk

Tesla’s Cybertruck, the hulking, stainless-steel pickup that inspired devotion and derision with its science-fiction looks, will cease production next year.

CEO Elon Musk announced the model’s demise Friday, November 6, with a curt post on X, his social media site, simply noting production of the vehicle “will be winding down” around the middle of 2027 at its facility outside Austin, Texas. Musk said the move was to allow increased production of its Cybercab robotaxi.

For the Cybertruck, a pet project of Musk who insisted it was Tesla’s best product, it marks an unceremonious end to one of the auto industry’s most ballyhooed debuts.

“Few vehicles in history have generated as much attention,” said Armen Hareyan, whose Torque News site covers autos. “The Cybertruck became a cultural symbol – loved, mocked and impossible to ignore.”

The Cybertruck rolled onto the scene in a dramatic unveiling in 2019, when a Tesla designer hurled a metal ball at the vehicle to demonstrate its supposedly unbreakable glass, only to see it shatter. He repeated the stunt on another window of the truck only to shatter that one, too.

Even as some critics scoffed, Musk was steadfast.

“I just wanted to make a futuristic battle tank — something that looks like it could come out of ‘Blade Runner’ or ‘Aliens’ or something like that but was also highly functional,” he told Automotive News. He called it “a better sports car than a Porsche 911” and “a better truck than an F-150.”

It struck some as the perfect vehicular reflection of the brash, convention-busting Musk.

“A really controversial vehicle unveiled by a controversial individual into a market where none of the electric trucks have been able to really capture demand,” said Spencer Penn, a former Tesla executive who left the company before the Cybertruck’s launch and now heads software developer LightSource.

Penn remembered watching the unveiling and feeling initially revolted by the sight of the Cybertruck, calling its appearance “madness.” But the more he looked at it, the more his opinion changed. He signed up for a pre-sale reservation, though ended up not getting a Cybertruck when Musk’s promises of a price tag under $40,000 went unmet and the first trucks sold for double or more. Penn called the Cybertruck part of Tesla’s adventurous spirit that drives innovation.

“Some of these bets work and some of these bets don’t,” he said.

While the decision to end Cybertruck production may be driven by sales realities, it's also a reflection of Tesla’s shift to autonomous vehicles, on which Musk is betting the company’s future.

Musk once forecast he’d make 250,000 Cybertrucks a year. Kelley Blue Book estimated Tesla sold just 20,237 of the vehicles last year, down about half from the year prior. Sales through the end of September this year were down another 28%, according to Kelley Blue Book.

If the imposing, sharp-angled, dystopian appearance of the Cybertruck weren’t enough to turn many potential buyers away, Musk did so himself by allying with a panoply of right-wing figures, most notably U.S. President Donald Trump. He alienated some customers as his image morphed from eccentric innovator to polarizing force trading his billions for political influence.

Once-passionate Tesla drivers rushed to sell off their cars, or slapped stickers on the bumper declaring, “I bought this before Elon went crazy.” Organizers staged demonstrations outside Tesla showrooms and urged investors to dump shares of the company’s stock. Anger spilled into violence, with Molotov cocktails hurled at Tesla vehicles, charging stations set ablaze, and dealerships covered in graffiti.

Lovers of the Cybertruck became targets, too, subjected to shouts of “Nazi!” and extended middle fingers.

Ross Blankenship is one of them. When he first laid eyes on the Cybertruck, he felt transported to a world from his childhood, when he would play “Halo,” the sci-fi video game. He had to have it.

“I had that sort of child in me wanting to be part of something cool that would change the future of automotive,” Blankenship said in a call from his Cybertruck as he drove through Sunnyside, Colorado. Even as Blankenship found he agreed with Musk on politics, he hated seeing a vehicle he loved turned into a political symbol. “I never bought it for any other reason than the fascination with the future technology of trucks … so that was a little heartbreaking.”

He would buy another Cybertruck again in a heartbeat, calling its end “a sad moment.”